Leukemia Research and Treatment · 2012 · 21 citations · 17 references
MedicineOncologyPharmacologyChemotherapyPharmacogeneticsPharmacogenomicsDrug Metabolism GeneticsPediatric Cancer GeneticsPediatric ChemotherapyPediatric LeukemiasPharmacogenomics In ChildrenPharmacogenomics In Pediatric OncologyDrug Metabolism PolymorphismsGenetic PolymorphismsMetabolic Pathway PolymorphismsMethylenetetrahydrofolate Reductase PolymorphismsPediatric Pharmacogenetic VariationPrognostic Factors Analysis
The influence of genic polymorphisms involved in metabolism of chemotherapeutic agents as the methotrexate (MTX) has been studied mainly in acute lymphoblastic leukemia (ALL) of childhood. Advances in treatment may be attributed to identification of prognostic factors added to chemotherapy protocol. The aim of this study was to analyze the association of the C677T, A1298C, and G80A polymorphisms on MTHFR gene and on the overall survival of pediatric patients (n = 126) with lymphoblastic leukemia treated with MTX according to the Brazilian protocol in 187 months. The C677T and G80A polymorphisms were genotyped by PCR-RFLP and A1298C polymorphism by allele-specific PCR. We observed that ALL patients presented rate (dead/alive) of 0.36 for the 677CC genotype, corresponding also to lower overall survival (P = 0.0013); on the other hand, the 677TT genotype showed a better survival (98%). Thus, we believe that patients with 80AA genotype presented a small reduction in MTX plasma level, suggesting that ALL children, carrying the 80AA genotype, showed a high toxicity to MTX (P < 0.0001).
17
Ancestry and pharmacogenetics of antileukemic drug toxicity
Shinji Kishi, Cheng Cheng, Deborah French et al. · Blood · 2007 · 205 citations · Full text
Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia
Róbert de Jonge, Wim J. E. Tissing, Jan Hendrik Hooijberg et al. · Blood · 2008 · 157 citations · Full text
Life Sciences, Genetics, Pediatrics +12